Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.99
NAS:BCRX's Cash-to-Debt is ranked lower than
81% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NAS:BCRX: 0.99 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.94  Med: No Debt Max: 11087.67
Current: 0.99
0.94
11087.67
Equity-to-Asset 0.04
NAS:BCRX's Equity-to-Asset is ranked lower than
91% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:BCRX: 0.04 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.23  Med: 0.6 Max: 0.98
Current: 0.04
-0.23
0.98
Piotroski F-Score: 2
Altman Z-Score: -7.14
Beneish M-Score: -2.59
WACC vs ROIC
24.45%
-328.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -262.21
NAS:BCRX's Operating Margin % is ranked lower than
62% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NAS:BCRX: -262.21 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BCRX' s Operating Margin % Range Over the Past 10 Years
Min: -756.28  Med: -105.32 Max: -18.42
Current: -262.21
-756.28
-18.42
Net Margin % -313.02
NAS:BCRX's Net Margin % is ranked lower than
64% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:BCRX: -313.02 )
Ranked among companies with meaningful Net Margin % only.
NAS:BCRX' s Net Margin % Range Over the Past 10 Years
Min: -702.16  Med: -118.9 Max: -18.03
Current: -313.02
-702.16
-18.03
ROE % -219.11
NAS:BCRX's ROE % is ranked lower than
91% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. NAS:BCRX: -219.11 )
Ranked among companies with meaningful ROE % only.
NAS:BCRX' s ROE % Range Over the Past 10 Years
Min: -544.61  Med: -69.75 Max: -20.28
Current: -219.11
-544.61
-20.28
ROA % -63.67
NAS:BCRX's ROA % is ranked lower than
74% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NAS:BCRX: -63.67 )
Ranked among companies with meaningful ROA % only.
NAS:BCRX' s ROA % Range Over the Past 10 Years
Min: -63.67  Med: -40.79 Max: -11.86
Current: -63.67
-63.67
-11.86
ROC (Joel Greenblatt) % -904.69
NAS:BCRX's ROC (Joel Greenblatt) % is ranked lower than
60% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:BCRX: -904.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15669.01  Med: -836.04 Max: -202.66
Current: -904.69
-15669.01
-202.66
3-Year Revenue Growth Rate 7.60
NAS:BCRX's 3-Year Revenue Growth Rate is ranked higher than
56% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:BCRX: 7.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -70.7  Med: -13.6 Max: 528
Current: 7.6
-70.7
528
3-Year EBITDA Growth Rate -8.90
NAS:BCRX's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:BCRX: -8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.9  Med: -8.9 Max: 63.7
Current: -8.9
-41.9
63.7
3-Year EPS without NRI Growth Rate -9.30
NAS:BCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NAS:BCRX: -9.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.4  Med: -5.1 Max: 52.9
Current: -9.3
-38.4
52.9
GuruFocus has detected 7 Warning Signs with Biocryst Pharmaceuticals Inc $NAS:BCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BCRX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BCRX Guru Trades in Q1 2016

John Paulson 263,100 sh (New)
Chuck Royce 160,000 sh (New)
Paul Tudor Jones 125,588 sh (+1022.83%)
Jim Simons 292,221 sh (+104.49%)
Joel Greenblatt Sold Out
» More
Q2 2016

BCRX Guru Trades in Q2 2016

John Paulson 263,100 sh (unchged)
Chuck Royce 160,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 16,687 sh (-86.71%)
» More
Q3 2016

BCRX Guru Trades in Q3 2016

John Paulson 363,100 sh (+38.01%)
Chuck Royce 160,000 sh (unchged)
Paul Tudor Jones 11,137 sh (-33.26%)
» More
Q4 2016

BCRX Guru Trades in Q4 2016

Jim Simons 49,903 sh (New)
John Paulson 350,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 144,000 sh (-10.00%)
John Paulson 52,600 sh (-85.51%)
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CLDX, NAS:NLNK, NAS:CYTK, NAS:TLGT, OTCPK:ABVC, NAS:AVDL, NAS:NVAX, NAS:CERS, NAS:PDLI, AMEX:BTX, NAS:LJPC, NAS:BSTC, NAS:ARNA, NAS:FOMX, NAS:SPPI, NAS:GERN, NAS:PRTK, OTCPK:CNBX, NAS:ADXS, NAS:OMED » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company's product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.

Ratios

vs
industry
vs
history
PB Ratio 101.65
BCRX's PB Ratio is ranked lower than
99% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. BCRX: 101.65 )
Ranked among companies with meaningful PB Ratio only.
BCRX' s PB Ratio Range Over the Past 10 Years
Min: 1.05  Med: 8.8 Max: 132.04
Current: 101.65
1.05
132.04
PS Ratio 18.35
BCRX's PS Ratio is ranked lower than
61% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. BCRX: 18.35 )
Ranked among companies with meaningful PS Ratio only.
BCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 6.97 Max: 669.35
Current: 18.35
0.66
669.35
Current Ratio 1.25
BCRX's Current Ratio is ranked lower than
84% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BCRX: 1.25 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.8  Med: 5.04 Max: 39.53
Current: 1.25
0.8
39.53
Quick Ratio 1.21
BCRX's Quick Ratio is ranked lower than
81% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. BCRX: 1.21 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 5.01 Max: 39.53
Current: 1.21
0.77
39.53
Days Inventory 2.00
BCRX's Days Inventory is ranked higher than
96% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BCRX: 2.00 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s Days Inventory Range Over the Past 10 Years
Min: 2  Med: 363.62 Max: 15234.51
Current: 2
2
15234.51
Days Sales Outstanding 99.14
BCRX's Days Sales Outstanding is ranked lower than
71% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. BCRX: 99.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.54  Med: 146.02 Max: 267.7
Current: 99.14
44.54
267.7
Days Payable 3.00
BCRX's Days Payable is ranked lower than
92% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. BCRX: 3.00 )
Ranked among companies with meaningful Days Payable only.
BCRX' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 9756.18 Max: 34806.57
Current: 3
3
34806.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.00
BCRX's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. BCRX: -13.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -8.3 Max: -0.6
Current: -13
-20.4
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 109.80
BCRX's Price-to-Tangible-Book is ranked lower than
99% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. BCRX: 109.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.33  Med: 4.33 Max: 131.2
Current: 109.8
0.33
131.2
Price-to-Median-PS-Value 2.64
BCRX's Price-to-Median-PS-Value is ranked lower than
89% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BCRX: 2.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 2.41 Max: 418.75
Current: 2.64
0.13
418.75
Earnings Yield (Greenblatt) % -15.50
BCRX's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. BCRX: -15.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.75  Med: 487.1 Max: 1563.9
Current: -15.5
-15.75
1563.9

More Statistics

Revenue (TTM) (Mil) $21.97
EPS (TTM) $ -0.94
Beta3.00
Short Percentage of Float15.77%
52-Week Range $1.74 - 7.56
Shares Outstanding (Mil)73.76

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 22 17 10 13
EPS ($) -0.94 -1.09 -1.01 -1.05
EPS without NRI ($) -0.94 -1.09 -1.01 -1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
A Trump Presidency May Be Good for Biotech Dec 16 2016 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? Feb 17 2017
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US :... Feb 17 2017
Coverage initiated on BioCryst Pharma by Ladenburg Thalmann Feb 16 2017
BioCryst to Announce Fourth Quarter and Year End 2016 Financial Results February 27 Feb 15 2017
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US :... Jan 31 2017
BioCryst plans for European launch of injectable flu therapy Jan 30 2017
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 30 2017
BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency Jan 30 2017
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? Jan 25 2017
BioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : January 23, 2017 Jan 23 2017
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : January 20, 2017 Jan 20 2017
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US :... Jan 20 2017
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
BioCryst Receives Health Canada Approval for RAPIVAB® for the Treatment of Influenza Jan 08 2017
BioCryst to Present at the J.P. Morgan Healthcare Conference Jan 04 2017
Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)? Dec 29 2016
Are Options Traders Betting on a Big Move in BioCryst (BCRX) Stock? Dec 22 2016
A Trump Presidency May Be Good for Biotech Dec 16 2016
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 16, 2016 Dec 16 2016
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 5, 2016 Dec 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)